Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: D11AH11

Anzupgo(Delgocitinib)

Dermatitis;Eczema

Marketing Authorisation Holder: LEO Pharma A/S

EMA Authorisation: 19/09/2024

INN: delgocitinib

Indication

Anzupgo is indicated for the treatment of moderate to severe chronic hand eczema (CHE)

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Anzupgo — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.